Stay updated with breaking news from Pharmaceutical Intelligence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas.
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).
(IO-102 + IO-103) is under clinical development by IO Biotech and currently in Phase II for Lung Adenocarcinoma.
OBI-999 is under clinical development by OBI Pharma and currently in Phase II for Breast Cancer.
AGEN-2373 is under clinical development by Agenus and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC).